Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:125659.
doi: 10.1155/2015/125659. Epub 2015 Jun 28.

Curative Effects of Fuzheng Huayu on Liver Fibrosis and Cirrhosis: A Meta-Analysis

Shu Dong  1 , Qi-Long Chen  1 , Shi-Bing Su  1
Affiliations
Review

Curative Effects of Fuzheng Huayu on Liver Fibrosis and Cirrhosis: A Meta-Analysis

Shu Dong et al. Evid Based Complement Alternat Med. 2015.

Abstract

The Fuzheng Huayu (FZHY) formula is being used in antiliver fibrosis treatment in China. For systemic evaluation of the curative effects of FZHY on liver fibrosis and cirrhosis progress, a total of 1392 subjects (714 cases and 678 controls) were found to be eligible for meta-analysis in this study. Standard mean differences (SMDs) with 95% confidence interval (CI) were calculated for changes between FZHY groups and controls by employing fixed effects or random effects model. In the overall analysis, alanine transaminase (ALT) (P = 0.003, SMD = -0.87, 95% CI: -1.46 to -0.29), total bilirubin (TBil) (P = 0.001, SMD = -1.30, 95% CI: -2.10 to -0.50), hyaluronic acid (HA) (P = 0.000, SMD = -0.94, 95% CI: -1.30 to -0.58), laminin (LN) (P = 0.000, SMD = -0.80, 95% CI: -1.20 to -0.41), type III procollagen (PC-III) (P = 0.000, SMD = -1.27, 95% CI: -1.93 to -0.60), and type IV procollagen (IV-C) (P = 0.000, SMD = -0.78, 95% CI: -1.05 to -0.51) were decreased after FZHY treatment; however, albumin (ALB) was increased (P = 0.037, SMD = 1.10, 95% CI: 0.07 to 2.12) significantly. Furthermore, the Child-Pugh score was reduced significantly and the life quality was improved after FZHY treatment in cirrhosis patients. The results of this meta-analysis indicated that FZHY effectively improves the liver function, alleviates hepatic fibrosis, decreases Child-Pugh score, and relieves TCM symptoms caused by liver dysfunction, indicating that FZHY may contribute to the alleviation of liver fibrosis and cirrhosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of studies identified with criteria for inclusion and exclusion.
Figure 2
Figure 2
Forest plots of ALT, AST, TBil, and ALB after treatment: (a) ALT, (b) AST, (c) TBil, and (d) ALB.
Figure 3
Figure 3
Forest plots of HA, LN, PC-III, and VI-C after treatment: (a) HA, (b) LN, (c) PC-III, and (d) VI-C.
See this image and copyright information in PMC

References

    1. Suk K. T., Kim D. J. Staging of liver fibrosis or cirrhosis: the role of hepatic venous pressure gradient measurement. World Journal of Hepatology. 2015;7(3):607–615. doi: 10.4254/wjh.v7.i3.607. - DOI - PMC - PubMed
    1. Rudolph K. L., Chang S., Millard M., Schreiber-Agus N., DePinho R. A. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 2000;287(5456):1253–1258. doi: 10.1126/science.287.5456.1253. - DOI - PubMed
    1. Liu C. H., Hu Y. Y., Xu L. M., Liu P. Effect of Fuzheng Huayu formula and its actions against liver fibrosis. Chinese Medicine. 2009;4(1, article 12) doi: 10.1186/1749-8546-4-12. - DOI - PMC - PubMed
    1. Dong S., Su S.-B. Advances in mesenchymal stem cells combined with traditional Chinese medicine therapy for liver fibrosis. Journal of Chinese Integrative Medicine. 2014;12(3):147–155. doi: 10.1016/s2095-4964(14)60022-4. - DOI - PubMed
    1. Sanodiya B. S., Thakur G. S., Baghel R. K., Prasad G. B. K. S., Bisen P. S. Ganoderma lucidum: a potent pharmacological macrofungus. Current Pharmaceutical Biotechnology. 2009;10(8):717–742. doi: 10.2174/138920109789978757. - DOI - PubMed

LinkOut - more resources